We are live on ! Find out more
AVIR icon

Atea Pharmaceuticals
AVIR

126 hedge funds and large institutions have $327M invested in Atea Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 50 increasing their positions, 34 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,376% more call options, than puts

Call options by funds: $13.4M | Put options by funds: $540K

47% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 34

7% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 15

0.06% less ownership

Funds ownership: 69.07% → 69.01% (-0.06%)

1% less funds holding

Funds holding: 127 → 126 (-1)

19% less capital invested

Capital invested by funds: $406M → $327M (-$79.2M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
126
Holders Change
-1
Holders Change %
-0.79%
% of All Funds
2.17%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
16
Increased
50
Reduced
34
Closed
15
Calls
$13.4M
Puts
$540K
Net Calls
+$12.8M
Net Calls Change
-$208K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$3.55M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$3.09M
3
ABG
Ally Bridge Group
New York
+$2.76M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.74M
5
First Trust Advisors
First Trust Advisors
Illinois
+$1.53M

Top Sellers

Rank Fund Capital Flow
1
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$8.03M
2
KPF
K2 Principal Fund
Ontario, Canada
-$7.66M
3
Voloridge Investment Management
Voloridge Investment Management
Florida
-$1.88M
4
Deutsche Bank
Deutsche Bank
Germany
-$1.8M
5
EC
EcoR1 Capital
California
-$1.19M
Name Holding Trade Value Shares
Change 		Change in
Stake
Royal Bank of Canada
101
Royal Bank of Canada
Ontario, Canada
$26K +$19.2K +2,507 +124%
Russell Investments Group
102
Russell Investments Group
United Kingdom
$25K +$6.93K +905 +25%
DA
103
Denali Advisors
California
$25K +$33.7K +4,400 New
Osaic Holdings
104
Osaic Holdings
Arizona
$24K – – –
Bank Julius Baer & Co
105
Bank Julius Baer & Co
Switzerland
$16K -$337 -44 -2%
CG
106
Cutler Group
California
$15K – – –
LSA
107
Leonteq Securities AG
Switzerland
$11.4K – – –
EC
108
Estate Counselors
Wisconsin
$5K -$15.3K -2,000 -67%
Wells Fargo
109
Wells Fargo
California
$4K -$4.76K -622 -47%
CUAMC
110
China Universal Asset Management Company
China
$4K +$5.97K +780 New
ZIG
111
Zullo Investment Group
Pennsylvania
$3K – – –
LC
112
Lindbrook Capital
California
$2K -$184 -24 -8%
S
113
SignatureFD
Georgia
$2K +$2.07K +271 +228%
US Bancorp
114
US Bancorp
Minnesota
$2K +$2.79K +364 New
QT
115
Quantbot Technologies
New York
$1K -$11.2K -1,463 -86%
CAM
116
Costello Asset Management
Pennsylvania
$1K – – –
Daiwa Securities Group
117
Daiwa Securities Group
Japan
$1K – – –
ODG
118
O'Dell Group
Ohio
$1K – – –
TSWM
119
Tyler-Stone Wealth Management
Ohio
$1K – – –
Voloridge Investment Management
120
Voloridge Investment Management
Florida
– -$1.88M -265,365 Closed
PFMU
121
Privium Fund Management (UK)
United Kingdom
– -$435K -61,284 Closed
Qube Research & Technologies (QRT)
122
Qube Research & Technologies (QRT)
United Kingdom
– -$426K -60,067 Closed
AI
123
Atom Investors
Texas
– -$219K -30,911 Closed
CSS
124
Cubist Systematic Strategies
Connecticut
– -$189K -26,656 Closed
GCP
125
GSA Capital Partners
United Kingdom
– -$178K -25,080 Closed
2 3 4
5
6

AVIR Hedge Fund Activity: Q3 2022 in Review

126 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Atea Pharmaceuticals (AVIR) for Q3 2022, worth a combined $327M — down 19% from $406M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new AVIR positions and 15 closed out — a net gain of 1 holder — while 50 added to existing stakes and 34 trimmed.

The largest buyer was BlackRock, adding an estimated $3.55M. The largest seller was Balyasny Asset Management, cutting an estimated $8.03M.

  • 126 institutional investors held Atea Pharmaceuticals (AVIR) as of Q3 2022, down from 127 in Q2 2022.
  • Funds reported $327M of Atea Pharmaceuticals stock for Q3 2022, down 19% quarter-over-quarter.
  • 16 funds opened new Atea Pharmaceuticals positions in Q3 2022 and 15 closed out, a net change of +1 holder.
  • The largest Atea Pharmaceuticals buyer in Q3 2022 was BlackRock, an estimated $3.55M added.
  • The largest Atea Pharmaceuticals seller in Q3 2022 was Balyasny Asset Management, an estimated $8.03M sold.

Based on aggregated 13F filings for Q3 2022.